Northwire Canada EditionTuesday, July 14, 2026
Sign inSubscribe
Northwire
⌕
WDO 26.04 −0.9% FVI 11.84 −1.6% OM 1.75 −1.7% ETG 2.99 +0.0% ARTG 31.47 −4.6% LUC 0.163 +1.6% AFM 1.38 +0.0% IMG 20.95 −3.5% CPAU 0.150 +3.5% MMX 0.075 +7.1% IE 12.47 −2.4% SASK 1.09 −1.8% MOG 0.390 +2.6% XIM 0.070 −6.7% S 0.110 −29.0% OMI 0.300 −4.8% WDO 26.04 −0.9% FVI 11.84 −1.6% OM 1.75 −1.7% ETG 2.99 +0.0% ARTG 31.47 −4.6% LUC 0.163 +1.6% AFM 1.38 +0.0% IMG 20.95 −3.5% CPAU 0.150 +3.5% MMX 0.075 +7.1% IE 12.47 −2.4% SASK 1.09 −1.8% MOG 0.390 +2.6% XIM 0.070 −6.7% S 0.110 −29.0% OMI 0.300 −4.8%

Healthcare

Page 47
  1. Mar 17, 2026 · 08:00 · AIDR

    Rocket Doctor AI Announces $2.049 Million Gross Proceeds from Warrant Exercises

    Rocket Doctor AI Announces $2.049 Million Gross Proceeds from Warrant Exercises

    01
  2. Mar 17, 2026 · 07:30 · GUD

    Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI(TM) (tafasitamab) for Follicular Lymphoma in Argentina and Mexico

    Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI(TM) (tafasitamab) for Follicular Lymphoma in Argentina and Mexico

    02
  3. Mar 17, 2026 · 07:25 · KNE

    Kane Biotech Announces Publication in Frontiers in Antibiotics Highlighting Advancements in Treating Antibiotic Tolerant Biofilms

    Kane Biotech Announces Publication in Frontiers in Antibiotics Highlighting Advancements in Treating Antibiotic Tolerant Biofilms

    03
  4. Mar 17, 2026 · 07:02 · TLT

    Theralase(R) Discovers Further Mechanism on How Ruvidar(R) Inactivates Herpes Simplex Virus

    Theralase(R) Discovers Further Mechanism on How Ruvidar(R) Inactivates Herpes Simplex Virus

    04
  5. Mar 17, 2026 · 07:00 · MBX

    Microbix Presents Reference-Material Innovations at EUROGIN

    Microbix Presents Reference-Material Innovations at EUROGIN

    05
  6. Mar 17, 2026 · 07:00 · EPRX

    Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis

    Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis

    06
  7. Mar 17, 2026 · 07:00 · WELL

    WELL Health Subsidiary WELLSTAR Expands National Billing Platform with Two Strategic Acquisitions, Now Serving Six Provinces

    WELL Health Subsidiary WELLSTAR Expands National Billing Platform with Two Strategic Acquisitions, Now Serving Six Provinces

    07
  8. Mar 17, 2026 · 03:05 · BNXT

    BioNxt Signs Strategic Agreement for Eurasian Commercialization Following Cladribine ODF Patent Grant in Eurasia and Europe

    BioNxt Signs Strategic Agreement for Eurasian Commercialization Following Cladribine ODF Patent Grant in Eurasia and Europe

    08
  9. Mar 16, 2026 · 22:55 · INNO

    Innocan closes $450,000 (U.S.) debenture offering

    Innocan closes $450,000 (U.S.) debenture offering

    09
  10. Mar 16, 2026 · 20:47 · SONA

    Sona Nanotech to hold investor webinar March 18

    Sona Nanotech to hold investor webinar March 18

    10
  11. Mar 16, 2026 · 17:15 · QIPT

    Quipt completes take-private deal w/ Kingswood, Forager

    Quipt completes take-private deal w/ Kingswood, Forager

    11
  12. Mar 16, 2026 · 17:03 · INNO

    Innocan Pharma Announces Closing of a Debenture to its Largest Shareholder, Tamar Innovest

    Innocan Pharma Announces Closing of a Debenture to its Largest Shareholder, Tamar Innovest

    12
  13. Mar 16, 2026 · 17:00 · HBP

    Helix BioPharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Six-Month Periods Ended January 31, 2026

    Helix BioPharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Six-Month Periods Ended January 31, 2026

    13
  14. Mar 16, 2026 · 08:08 · FRX

    Fennec Pharmaceuticals Announces Settlement Agreement Resolving PEDMARK Patent Litigation

    Fennec Pharmaceuticals Announces Settlement Agreement Resolving PEDMARK Patent Litigation

    14
← Newer Older →